Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin: A propensity score matched analysis

Thrombosis and Haemostasis

Volumn 116, Issue 5, 2016, Pages 975-986

  Lip, Gregory Y H ^a,b   Keshishian, Allison ^c   Kamble, Shital ^d   Pan, Xianying ^d   Mardekian, Jack ^e   Horblyuk, Ruslan ^e   Hamilton, Melissa ^d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

^c STATINMED RESEARCH   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e PFIZER INC   (United States)

Author keywords

Apixaban; Dabigatran; Major bleeding; Non valvular atrial fibrillation; Rivaroxaban; Warfarin

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DYSPEPSIA; FEMALE; HEALTH INSURANCE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; VENOUS THROMBOEMBOLISM; COMPARATIVE STUDY; MIDDLE AGED; RISK; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DABIGATRAN; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROPENSITY SCORE; PYRAZOLES; PYRIDONES; RETROSPECTIVE STUDIES; RISK; RIVAROXABAN; STROKE; WARFARIN;

EID: 84994662845     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-05-0403     Document Type: Article

References (25)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med 1987; 147: 1561-1564.
2. Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med 2007; 39: 371-391.
3. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol 2014; 64: e1-76.
4. Hart RG, Pearce LA, Aguilar MM. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007; 147: 590-592.
5. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Thromb Haemost 2013; 110: 1087-1107.
6. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123: 638-645.
7. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962.
8. Cunningham A, Stein CM, Chung CP, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 2011; 20: 560-566.
9. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011; 365: 981-992.
10. Pattanayak CW, Rubin DB, Zell ER. Propensity score methods for creating covariate balance in observational studies. Rev Esp Cardiol 2011; 6410: 897-903.
11. Baser O. Too Much Ado about Propensity Score Models? Comparing Methods of Propensity Score Matching. Value Health 2006; 9: 377-385.
12. Austin, PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Behavioral Res 2011; 46: 399-424.
13. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2010; 361: 1139-1151.
14. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011; 365: 883-891.
15. Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016; 37: 1145-1153.
16. Abraham NS, Singh S, Akexander GC et al. Comparative Risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. Br Med J 2015; 350: h1857.
17. Seeger JD, Bykov K, Bartels DB, et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015; 114: 1277-1289.
18. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. New Engl J Med 2013; 368: 1272-1274.
19. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation. Circulation 2015; 131: 157-163.
20. Lip GY, Larsen TB, Skjoth F, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012; 60: 738-746.
21. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012; 108: 476-484.
22. Larsen TB, Skjøth F, Nielsen PB, et al.. Comparative effectiveness and safety of nonvitamin antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Br Med J 2016; 350: i3189
23. Ho CW, Ho MH, Chan PH, et al. Ischaemic stroke and intracranial haemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke 2015; 46: 23-30.
24. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
25. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation 2016; 133: 601-609.